Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vizoovet is a Swiss veterinary biotechnology company specializing in advanced ophthalmic solutions for companion animals and horses. The company developed the first biomimetic tear film supplement designed specifically to match the unique physiological composition of animal tears, which differs significantly from human tears. Its flagship product, Vizoovet, is used to treat keratoconjunctivitis sicca (dry eye) and support the healing of corneal ulcers by restoring the natural protective layers of the ocular surface. By incorporating essential proteins and lipids, the company's technology aims to provide long-lasting lubrication and promote corneal health in veterinary patients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vizoovet.